Volume 131,400 in Canada Someone wanted off the bus. With $13 million cash and no debt, a profitable base business set to potentially accelerate with Symrise, Health Canada approval for a Phase I/IIa clinical trial targeting large markets, PGX moving towards commercial production after bioavailability testing, and the fibrosis opportunity CZO is absurdly, absurdly cheap.